Edition:
India

Insulet Corp (PODD.OQ)

PODD.OQ on NASDAQ Stock Exchange Global Select Market

68.25USD
9:10pm IST
Change (% chg)

$0.21 (+0.31%)
Prev Close
$68.04
Open
$68.13
Day's High
$68.47
Day's Low
$67.47
Volume
123,778
Avg. Vol
180,704
52-wk High
$72.98
52-wk Low
$36.80

Latest Key Developments (Source: Significant Developments)

Insulet announces pricing of convertible senior notes due 2024
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Insulet Corp :Insulet announces pricing of convertible senior notes due 2024.Insulet Corp - ‍priced a private placement of $350 million principal amount of convertible senior notes due 2024​.Insulet Corp - ‍size of offering increased from previously announced $300 million principal amount​.  Full Article

Insulet announces private offering of convertible senior notes
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Insulet Corp :Insulet announces private offering of convertible senior notes.Insulet Corp says ‍to offer $300 million principal amount of convertible senior notes due 2024 in a private placement​.Insulet - ‍intends to grant initial purchasers of notes option to buy up to an additional $45 million principal amount of notes​.  Full Article

Insulet Corp reports Q3 loss per share $0.04
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Insulet Corp :Insulet reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $121.8 million versus I/B/E/S view $114.4 million.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Sees fy 2017 revenue up 25 percent.Sees fy 2017 revenue $456 million to $459 million.  Full Article

Insulet announces private offering of convertible senior notes
Wednesday, 7 Sep 2016 

Insulet Corp : Insulet announces private offering of convertible senior notes .Insulet Corp says to offer $250 million principal amount of convertible senior notes due 2021 (notes) in a private placement.  Full Article

Insulet Corp reports Q2 loss per share of $0.08 from cont ops
Thursday, 4 Aug 2016 

Insulet Corp : Insulet reports second quarter 2016 financial results . Q2 loss per share $0.08 from continuing operations . Q2 revenue $87.3 million versus I/B/E/S view $81.2 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Sees revenue guidance for 2016 in range of $345 to $355 million .FY2016 revenue view $337.4 million -- Thomson Reuters I/B/E/S.  Full Article

Insulet Corp reaffirms FY 2016 revenue guidance; gives Q2 2016 revenue guidance
Friday, 29 Apr 2016 

Insulet Corp:For FY 2016, the Company is reaffirming its revenue guidance of $330 to $350 million.For Q2 2016, the Company is introducing revenue guidance in the range of $81 to $84 million.  Full Article

Insulet Corp announces development partner for the omnipod artificial pancreas
Thursday, 25 Feb 2016 

Insulet Corp:License agreement and partnership with Mode AGC to develop and incorporate advanced artificial pancreas algorithm created by renowned researchers Francis Doyle PhD, Eyal Dassau PhD, and Howard Zisser MD.  Full Article

Insulet Corporation to divest neighborhood diabetes supplies business
Wednesday, 3 Feb 2016 

Insulet Corporation:To divest neighborhood diabetes supplies business.To sell wholly-owned neighborhood diabetes supplies business for $5 million in cash.Transaction is expected to improve insulet's gross margins on an annual basis by low-to-mid single digits.Says company expects non-recurring charges of approximately $10 million in the fourth quarter of 2015.Says company expects additional charges in the first quarter of 2016.Transaction to be accretive to earnings, excluding non-recurring charges,transition costs related to the sale of the business.Says Covington associates acted as financial advisor and hogan lovells US llp acted as legal advisor to Insulet.Says to sell its wholly-owned neighborhood diabetes supplies business to liberty medical, llc.  Full Article

Insulet Corp enters into development agreement with Eli Lilly for OmniPod Delivery of U200 Concentrated Insulin
Tuesday, 12 Jan 2016 

Insulet Corp:Announced it has entered into a development agreement with Eli Lilly and Company (Lilly) to develop a new version of Insulet's OmniPod tubeless insulin delivery system, specifically designed to deliver Lilly's Humalog 200 units/mL insulin.  Full Article